Mirum Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops therapies for the treating of cholestatic liver diseases. Mirum Pharmaceuticals serves patients in the United States.

Current Report (Form 8-K | Period ending 2025-12-06)

Current Report (Form 8-K | Period ending 2025-11-17)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mirum Pharmaceuticals (MIRM US)

Current Report (Form 8-K | Period ending 2025-12-06)

Current Report (Form 8-K | Period ending 2025-11-17)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-04)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)